T. Rowe Price Investment Management, Inc. Moon Lake Immunotherapeutics Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 509 shares of MLTX stock, worth $4,662. This represents 0.0% of its overall portfolio holdings.
Number of Shares
509Holding current value
$4,662% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding MLTX
# of Institutions
157Shares Held
54.5MCall Options Held
799KPut Options Held
661K-
Bvf Inc San Francisco, CA19.8MShares$181 Million36.63% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$77.8 Million40.43% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.15MShares$38 Million3.57% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.61MShares$23.9 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.67MShares$15.3 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $338M
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...